Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.33 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.33 |
| ▸ | GABRP | O00591 | 1/20 | 0.33 |
| ▸ | GABRD | O14764 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.33 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.33 |
| ▸ | GABRE | P78334 | 1/20 | 0.33 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.33 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.33 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5168218 | 0.86 | IDUA (0.32) | ALDH1A1 | |
| SCHEMBL23002195 | 0.84 | — | — | |
| Hydrochloric Acid SCHEMBL19138196 | 0.83 | — | — | |
| SCHEMBL4233982 | 0.80 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL9289233 | 0.76 | TSHR (0.35) | TSHRLMNASLC6A1PMP22SLC6A11 | |
| SCHEMBL3412783 | 0.75 | — | — | |
| SCHEMBL4078884 | 0.75 | ALDH1A1 (0.32) | TSHRLMNAPMP22SLC6A11GABRP | |
| SCHEMBL8630981 | 0.73 | GRIA2 (0.34) | TSHRALDH1A1ALOX15CYP2D6CYP1A2 | |
| SCHEMBL2572584 | 0.72 | SLC6A1 (0.38) | TSHRLMNASLC6A1PMP22SLC6A11 | |
| SCHEMBL3974964 | 0.70 | MCL1 (0.36) | TSHRLMNASLC6A1SLC6A11SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4778420-B2 | — | — | 2011-09-21 | — | — | JP | claimed |
| US-20090281308-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED, INC. (CA) | 2009-11-12 | — | — | US | claimed |
| EP-1615633-A4 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED INC (CA) | 2008-07-09 | — | — | EP | claimed |
| CN-1777423-A | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED INC (CA) | 2006-05-24 | — | — | CN | claimed |
| EP-1615633-A2 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED INC. (CA) | 2006-01-18 | — | — | EP | claimed |
| US-20050059702-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED CORPORATION (CA) | 2005-03-17 | — | — | US | claimed |
| WO-2004093817-A2 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED INC. (CA) | 2004-11-04 | — | — | WO | claimed |
| EP-2374804-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | Genzyme Corporation (US) | 2011-10-12 | — | — | EP | disclosed |
| CN-101941964-A | Has the Chemokine Receptors bonded heterogeneous ring compound that promotes effect | ANORMED INC | 2011-01-12 | — | — | CN | disclosed |
| US-20100178271-A1 | Combination Therapy | GENZYME CORPORATION (US) | 2010-07-15 | — | — | US | disclosed |
| US-20100003224-A1 | Combination Therapy | GENZYME CORPORATION (US) | 2010-01-07 | — | — | US | disclosed |
| US-20090281308-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED, INC. (CA) | 2009-11-12 | — | — | US | disclosed |
| US-7550484-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | GENZYME CORPORATION (US) | 2009-06-23 | — | — | US | disclosed |
| CN-1777423-A | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED INC (CA) | 2006-05-24 | — | — | CN | disclosed |
| WO-2006020891-A2 | CHEMOKINE COMBINATIONS TO MOBILIZE PROGENITOR/STEM CELLS | ANORMED INC. (CA) | 2006-02-23 | — | — | WO | disclosed |
| US-20060035829-A1 | Chemokine combinations to mobilize progenitor/stem cells | ANORMED INC. | 2006-02-16 | — | — | US | disclosed |
| EP-1615633-A2 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED INC. (CA) | 2006-01-18 | — | — | EP | disclosed |
| WO-2005049778-A1 | LIGAND AND COMPLEX FOR CATALYTICALLY BLEACHING A SUBSTRATE | UNILEVER PLC (GB) | 2005-06-02 | — | — | WO | disclosed |
| US-20050059702-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED CORPORATION (CA) | 2005-03-17 | — | — | US | disclosed |
| WO-2004093817-A2 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED INC. (CA) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035829-A1 | Chemokine combinations to mobilize progenitor/stem cells | CXCL12, CXCR2, CXCR4 | TSHR 2728/4885LMNA 4492/4885SLC6A1 3176/4885 |
| US-20050059702-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | CXCR4, CXCR1, CCR5 | TSHR 1287/4885LMNA 4869/4885SLC6A1 4816/4885 |
| US-20090281308-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | CXCR4, CXCR1, CCR5 | TSHR 1287/4885LMNA 4869/4885SLC6A1 4816/4885 |
| US-20100178271-A1 | Combination Therapy | CXCL12, CSF3R, CXCR4 | TSHR 1447/4885LMNA 4616/4885SLC6A1 3577/4885 |
| US-20100003224-A1 | Combination Therapy | CXCL12, CXCR4, SDF4 | TSHR 3304/4885LMNA 2421/4885SLC6A1 2393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.